Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Shares Outstanding (Weighted Average) (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Shares Outstanding (Weighted Average) for 17 consecutive years, with $92.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 2.21% to $92.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $92.6 million through Dec 2025, up 2.21% year-over-year, with the annual reading at $92.6 million for FY2025, 2.21% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $92.6 million at Myriad Genetics, roughly flat from $92.3 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $92.6 million in Q4 2025, with the low at $76.0 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $84.4 million, with a median of $81.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) grew 1.12% in 2023, then increased 11.4% in 2024.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $78.0 million in 2021, then rose by 3.33% to $80.6 million in 2022, then increased by 2.73% to $82.8 million in 2023, then rose by 9.42% to $90.6 million in 2024, then rose by 2.21% to $92.6 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $92.6 million, $92.3 million, and $92.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.